Cargando…

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting

Background: Quality of life in men is influenced by general health, sexual function and urinary function. These components are associated with both weight and inflammatory status. Material and Methods: 805 men with hypogonadism are enrolled in a registry study in a urological office. 412 received TT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haider, Karim, Haider, Ahmad, Doros, Gheorghe, Traish, Abdulmaged, Saad, Farid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553163/ http://dx.doi.org/10.1210/js.2019-SUN-226

Ejemplares similares

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study
por: Haider, Karim Sultan, et al.
Publicado: (2020)

Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups
por: Traish, Abdulmaged M., et al.
Publicado: (2017)

Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years
por: Haider, Ahmad, et al.
Publicado: (2014)

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men
Publicado: (2021)

Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2021)

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study
por: Traish, A M, et al.
Publicado: (2014)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2016)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men
por: White, William B., et al.
Publicado: (2021)

Erratum: Correction of the references for Figures. Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2017)

Testosterone and weight loss: the evidence
por: Traish, Abdulmaged M.
Publicado: (2014)

SUN-222 Testosterone Treatment in Men with Classical vs. Functional Hypogonadism: A 9-Year Registry
por: Zitzmann, Michael, et al.
Publicado: (2019)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020)

Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study
por: Saad, F., et al.
Publicado: (2020)

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome
por: Traish, Abdulmaged M., et al.
Publicado: (2018)

SUN-227 Monitoring Testosterone (T) Levels in Men Receiving Oral Testosterone Undecanoate (TU): Challenges Due to Post-Collection Conversion of TU-to-T and a Path Forward
por: Swerdloff, Ronald, et al.
Publicado: (2019)

Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
por: Haider, Ahmad, et al.
Publicado: (2014)

Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men
por: Saad, Farid, et al.
Publicado: (2015)

Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021)

SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights
por: Campbell, Katherine, et al.
Publicado: (2023)

Oral testosterone undecanoate is an effective treatment for micropenis therapy
por: Saenger, Paul, et al.
Publicado: (2021)

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
por: Saad, Farid, et al.
Publicado: (2018)

SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate
por: Dobs, Adrian Sandra, et al.
Publicado: (2020)

Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats
por: An, Jinho, et al.
Publicado: (2022)

UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism
por: Bang, Anne Kirstine, et al.
Publicado: (2013)

Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate
por: Zgair, Atheer, et al.
Publicado: (2021)

Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer
por: Morgentaler, Abraham, et al.
Publicado: (2020)

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
por: Haider, Ahmad, et al.
Publicado: (2016)

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
por: Yassin, AA, et al.
Publicado: (2013)

PMON267 Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®)
por: Swerdloff, Ronald, et al.
Publicado: (2022)

Foreword by President of INAE
por: Mishra, Sanak
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jmaq2ragselv5gcvq167nj6hu1